Forest to bid

September 1995
Crain's New York Business;9/18/95, Vol. 11 Issue 38, p50
Reports on Forest Laboratories Inc.'s plan to announce a tender offer of 22% of Biovail Corp. International as part of a licensing agreement for Biovail's approved heart drug.


Related Articles

  • CNS News Round-Up.  // PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p2 

    Reports developments in the pharmaceutical industry. Decline in the stock price of Biovail Corp.; Market withdrawal of Celebrex drug by Pfizer Inc. in Turkey; Acceptance of the supplemental new drug application of Forest Laboratories Inc. by the U.S. Food and Drug Administration.

  • CENTRAL NERVOUS SYSTEM.  // MPR - Urologists' Edition;Spring/Summer2009, Vol. 6 Issue 1, p110 

    The article evaluates several pharmaceutical products which treat patients with central nervous system diseases including Ativan from Biovail Corp., Klonopin from Roche and Lexapro from Forest Corp.

  • BIOVAIL EXTENDS MARKETING PACT FOR ZOVIRAX OINTMENT/CREAM.  // Worldwide Biotech;Feb2003, Vol. 15 Issue 2, p2 

    Reports on the extension of the marketing agreement between Biovail Corp. and GlaxoSmithKline Plc for the Zovirax (R) Ointment and Zovirax Cream, as of February 2003.

  • A tough pill to swallow. Sparks, Debra // Financial World;11/18/96, Vol. 165 Issue 14, p42 

    Questions the valuation of the stock of Biovail, which has launched the hypertension drug Tiazac. Institutional investors buying into the company; Competition posed by Cardizem, another drug; Consequences of the failure to genericize Procardia XL.

  • FDA APPROVES BIOVAIL'S GENERIC PROCARDIA XL 30MG DOSAGE.  // Worldwide Biotech;Mar2001, Vol. 13 Issue 3, p1 

    Reports on the final approval granted by the United States Food and Drug Administration to Biovail Corporation's generic Procardia XL drug.

  • Canadian pharmaceutical to expand. Garza, Daniel R. // Caribbean Business;3/4/1999, Vol. 27 Issue 8, p2 

    Focuses on the additional employees projected by Biovail Corp. for its pharmaceutical manufacturing facility in Puerto Rico following the approval of its hypertension drug by the United States Food & Drug Administration (FDA).

  • Drugmaker Forest branches out. Benson, Barbara // Crain's New York Business;10/16/95, Vol. 11 Issue 42, p31 

    Profiles drug marketing company Forest Laboratories Inc. Reputation as a small niche firm; Marketing strategy placing Forest in direct competition with major pharmaceutical companies; Acquisition of products such as Climara and Tiazac.

  • Local drug company swallows bitter pill: First year of losses. Temes, Judy // Crain's New York Business;05/26/97, Vol. 13 Issue 21, p3 

    Reports that Forest Laboratories Incorporated recorded a $25 million loss in its fiscal year which ended March 31, 1997. Decrease in the revenue of the company; Information on the company's plans for growth; Reason for the Forest Laboratories' losses.

  • Forest Laboratories: Beyond the trees. Reingold, Jennifer // FW; 

    Presents a financial profile of Forest Laboratories. Appraisal and forecasting of stock price; Appraisal of consumer demand for the firm's drugs; Drugs currently being developed; Potential for further profits.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics